caa a22 4500 445299134 CHVBK 20180317142551.0 cr unu---uuuuu 170323e20100901xx s 000 0 eng 10.1007/s11940-010-0083-8 doi (NATIONALLICENCE)springer-10.1007/s11940-010-0083-8 Hixson John University of California San Francisco, 400 Parnassus Avenue, 94143, San Francisco, CA, USA aut Stopping Antiepileptic Drugs: When and Why? [Elektronische Daten] [John Hixson] Opinion statement: After a patient has initiated an antiepileptic drug (AED) and achieved a sustained period of seizure freedom, the bias towards continuing therapy indefinitely can be substantial. Studies show that the rate of seizure recurrence after AED withdrawal is about two to three times the rate in patients who continue AEDs, but there are many benefits to AED withdrawal that should be evaluated on an individualized basis. AED discontinuation may be considered in patients whose seizures have been completely controlled for a prolonged period, typically 1 to 2years for children and 2 to 5years for adults. For children, symptomatic epilepsy, adolescent onset, and a longer time to achieve seizure control are associated with a worse prognosis. In adults, factors such as a longer duration of epilepsy, an abnormal neurologic examination, an abnormal EEG, and certain epilepsy syndromes are known to increase the risk of recurrence. Even in patients with a favorable prognosis, however, the risk of relapse can be as high as 20% to 25%. Before withdrawing AEDs, patients should be counseled about their individual risk for relapse and the potential implications of a recurrent seizure, particularly for safety and driving. The Author(s), 2010 Current Treatment Options in Neurology Current Science Inc. 12/5(2010-09-01), 434-442 1092-8480 12:5<434 2010 12 11940 https://doi.org/10.1007/s11940-010-0083-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11940-010-0083-8 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Hixson John University of California San Francisco, 400 Parnassus Avenue, 94143, San Francisco, CA, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Neurology Current Science Inc 12/5(2010-09-01), 434-442 1092-8480 12:5<434 2010 12 11940 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer